These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 17718665)

  • 1. Public/private partnerships for prescription drug coverage: policy formulation and outcomes in Quebec's universal drug insurance program, with comparisons to the Medicare prescription drug program in the United States.
    Pomey MP; Forest PG; Palley HA; Martin E
    Milbank Q; 2007 Sep; 85(3):469-98. PubMed ID: 17718665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the effects of Quebec's private-public drug insurance system.
    Morgan SG; Gagnon MA; Charbonneau M; Vadeboncoeur A
    CMAJ; 2017 Oct; 189(40):E1259-E1263. PubMed ID: 29018085
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmaceuticals: Medicare Modernization Act--2005. End of Year Issue Brief.
    Seay M
    Issue Brief Health Policy Track Serv; 2005 Dec; ():1-21. PubMed ID: 16710928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medicare program; Medicare prescription drug benefit. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2005 Jan; 70(18):4193-585. PubMed ID: 15678603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimated cost of universal public coverage of prescription drugs in Canada.
    Morgan SG; Law M; Daw JR; Abraham L; Martin D
    CMAJ; 2015 Apr; 187(7):491-497. PubMed ID: 25780047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A political history of medicare and prescription drug coverage.
    Oliver TR; Lee PR; Lipton HL
    Milbank Q; 2004; 82(2):283-354. PubMed ID: 15225331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The interaction of partial public insurance programs and residual private insurance markets: evidence from the US Medicare program.
    Finkelstein A
    J Health Econ; 2004 Jan; 23(1):1-24. PubMed ID: 15154686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surviving and thriving in the medicare part D market. Long-term partnerships can help health plans meet requirements.
    Bridge L
    AHIP Cover; 2006; 47(4):52, 54, 57. PubMed ID: 16894855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A case study and state of science review: private versus public healthcare financing.
    Sampath P; Wilson D
    Glob J Health Sci; 2011 Dec; 4(1):118-26. PubMed ID: 22980105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medicare prescription drug coverage: consumer information and preferences.
    Winter J; Balza R; Caro F; Heiss F; Jun BH; Matzkin R; McFadden D
    Proc Natl Acad Sci U S A; 2006 May; 103(20):7929-34. PubMed ID: 16682629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies for containing drug costs: implications for a Medicare benefit.
    Cook AE
    Health Care Financ Rev; 1999; 20(3):29-37. PubMed ID: 10558018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-related prescription nonadherence in the United States and Canada: a system-level comparison using the 2007 International Health Policy Survey in Seven Countries.
    Kennedy J; Morgan S
    Clin Ther; 2009 Jan; 31(1):213-9. PubMed ID: 19243719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Purchasing Medicare prescription drug benefits: a new proposal.
    Etheredge L
    Health Aff (Millwood); 1999; 18(4):7-19. PubMed ID: 10425838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Medicare Prescription Drug Improvement and Modernization Act: prescription drugs and academic medicine.
    Frencher SK; Glied S
    Acad Med; 2006 Sep; 81(9):812-6. PubMed ID: 16936488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medicare program; Medicare prescription drug discount card. Interim final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2003 Dec; 68(240):69839-927. PubMed ID: 14674398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insurance coverage for prescription drugs: effects on use and expenditures in the Medicare population.
    Lillard LA; Rogowski J; Kington R
    Med Care; 1999 Sep; 37(9):926-36. PubMed ID: 10493470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medicare advantage: déjà vu all over again?
    Biles B; Dallek G; Nicholas LH
    Health Aff (Millwood); 2004; Suppl Web Exclusives():W4-586-97. PubMed ID: 15601665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PDP or MA-PD? Medicare part D enrollment decisions in CMS Region 25.
    Cline RR; Worley MM; Schondelmeyer SW; Schommer JC; Larson TA; Uden DL; Hadsall RS
    Res Social Adm Pharm; 2010 Jun; 6(2):130-42. PubMed ID: 20511112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimated effects of adding universal public coverage of an essential medicines list to existing public drug plans in Canada.
    Morgan SG; Li W; Yau B; Persaud N
    CMAJ; 2017 Feb; 189(8):E295-E302. PubMed ID: 28246223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medicare program; establishment of the Medicare advantage program. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2005 Jan; 70(18):4587-741. PubMed ID: 15678604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.